Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00851955|
Recruitment Status : Completed
First Posted : February 26, 2009
Last Update Posted : January 12, 2016
|Condition or disease|
|Chronic Pancreatitis Pancreatic Cancer|
|Study Type :||Observational|
|Actual Enrollment :||150 participants|
|Official Title:||Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer|
|Study Start Date :||May 2007|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||November 2011|
1. Normal pancreas patients
Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
2. Chronic pancreatitis patients
Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
3. Pancreatic cancer patients
Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
- All cause mortality [ Time Frame: One year ]
- For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice. [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00851955
|United States, Florida|
|Jacksonville, Florida, United States, 32224|
|Principal Investigator:||Massimo Raimondo, MD||Mayo Clinic|